T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$2.16B |
| 2 |
GE Aerospace
GE
|
+$1.93B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.62B |
| 4 |
Eli Lilly
LLY
|
+$1.59B |
| 5 |
SPLK
Splunk Inc
SPLK
|
+$1.38B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$2.72B |
| 2 |
Booking.com
BKNG
|
+$2.61B |
| 3 |
RHT
Red Hat Inc
RHT
|
+$1.62B |
| 4 |
JPMorgan Chase
JPM
|
+$1.43B |
| 5 |
State Street
STT
|
+$1.29B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.46% |
| 2 | Technology | 17.53% |
| 3 | Financials | 14.18% |
| 4 | Consumer Discretionary | 14.02% |
| 5 | Communication Services | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
Constellation Brands
STZ
$23.3B
| $112M | 0.02% |
693,436
+136,837
| +25% | +$27.2M |
|
577
Acadia Pharmaceuticals
ACAD
$4.89B
| $111M | 0.02% |
6,856,137
+3,667,519
| +115% | +$71.2M |
|
578
AutoZone
AZO
$49.6B
| $111M | 0.02% |
131,879
-7,803
| -6% | -$6.25M |
|
579
Capital One
COF
$137B
| $111M | 0.02% |
1,461,976
+36,261
| +3% | +$3.14M |
|
|
EBSB
580
DELISTED
Meridian Bancorp, Inc.
EBSB
| $110M | 0.02% |
7,682,529
+572,097
| +8% | +$9.01M |
|
581
Goldman Sachs
GS
$304B
| $110M | 0.02% |
657,594
+41,076
| +7% | +$8.29M |
|
582
US Physical Therapy
USPH
$1.24B
| $109M | 0.02% |
1,066,303
-53,650
| -5% | -$5.96M |
|
583
Pentair
PNR
$10.7B
| $109M | 0.02% |
2,884,283
-2,096,588
| -42% | -$84.7M |
|
584
Workiva
WK
$4.01B
| $109M | 0.02% |
3,024,266
+1,575,165
| +109% | +$55.4M |
|
585
Agios Pharmaceuticals
AGIO
$2B
| $108M | 0.02% |
2,352,730
-477,287
| -17% | -$29.5M |
|
586
Matsons
MATX
$6.39B
| $108M | 0.02% |
3,378,404
-128,078
| -4% | -$4.74M |
|
587
The Ensign Group
ENSG
$10.6B
| $108M | 0.02% |
2,971,526
+282,630
| +11% | +$11M |
|
588
KT
KT
$9.03B
| $108M | 0.02% |
7,559,815
-42,900
| -0.6% | -$621K |
|
|
ARRY
589
DELISTED
Array Biopharma Inc
ARRY
| $107M | 0.02% |
7,527,958
+1,376,845
| +22% | +$20.9M |
|
590
Heritage Financial
HFWA
$1.23B
| $107M | 0.02% |
3,599,793
+6,759
| +0.2% | +$221K |
|
|
NUVA
591
DELISTED
NuVasive, Inc.
NUVA
| $106M | 0.02% |
2,145,981
-197,532
| -8% | -$11.9M |
|
|
GWR
592
DELISTED
Genesee & Wyoming Inc.
GWR
| $106M | 0.02% |
1,428,949
+35,930
| +3% | +$2.88M |
|
|
BNCL
593
DELISTED
Beneficial Bancorp, Inc.
BNCL
| $106M | 0.02% |
7,390,138
+5,564
| +0.1% | +$86.2K |
|
594
Teva Pharmaceuticals
TEVA
$42.6B
| $106M | 0.02% |
6,844,186
+639,968
| +10% | +$13.1M |
|
|
KYNB
595
Kyntra Bio
KYNB
$28.5M
| $105M | 0.02% |
91,092
-2,591
| -3% | -$2.91M |
|
596
KLA
KLAC
$274B
| $105M | 0.02% |
11,775,990
-77,228,790
| -87% | -$719M |
|
|
STFC
597
DELISTED
State Auto Financial Corp
STFC
| $105M | 0.02% |
3,079,045
-41,465
| -1% | -$1.35M |
|
598
Liberty Latin America Class C
LILAK
$1.65B
| $105M | 0.02% |
8,386,580
+143,687
| +2% | +$2.22M |
|
599
Hubbell
HUBB
$26.8B
| $104M | 0.02% |
1,051,556
-156,848
| -13% | -$17.2M |
|
600
PennyMac Financial
PFSI
$4.13B
| $104M | 0.02% |
4,897,731
+1,018,909
| +26% | +$20.9M |
|
Similar funds
T. Rowe Price Associates's Q4 2018 Portfolio in Review
As of Q4 2018, T. Rowe Price Associates held 2,656 positions worth $591B, down 14% from $685B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q4 2018 filing shows 75 new, 1,551 increased, 819 reduced and 97 closed positions. Its largest new stake was StoneCo: 28,883,228 shares worth $519M. The largest sale was Tesla, an estimated $2.72B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Financials.
- T. Rowe Price Associates's largest Q4 2018 buy was StoneCo: 28,883,228 shares worth $519M.
- T. Rowe Price Associates added most to Meta Platforms (Facebook) in Q4 2018, an estimated $2.16B increase.
- T. Rowe Price Associates's biggest Q4 2018 reduction was Tesla, cutting an estimated $2.72B.
- T. Rowe Price Associates fully exited Aetna Inc in Q4 2018, selling an estimated $600M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $591B portfolio in Q4 2018.
- T. Rowe Price Associates opened 75 new positions and closed 97 in Q4 2018.
- T. Rowe Price Associates's portfolio value fell 14% quarter-over-quarter to $591B.
Based on T. Rowe Price Associates's 13F filing for Q4 2018, filed 14 Feb 2019.